We aimed to prospectively validate an optimized combination dosage regimen against a clinical carbapenem-resistant (CRAB) isolate (imipenem MIC, 32 mg/liter; tobramycin MIC, 2 mg/liter). Imipenem at constant concentrations (7.6, 13.4, and 23.3 mg/liter, reflecting a range of clearances) was simulated in a 7-day hollow-fiber infection model (inoculum, ∼10 CFU/ml) with and without tobramycin (7 mg/kg q24h, 0.5-h infusions). While monotherapies achieved no killing or failed by 24 h, this rationally optimized combination achieved >5 log bacterial killing and suppressed resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913956 | PMC |
| http://dx.doi.org/10.1128/AAC.02053-17 | DOI Listing |
Publication Analysis
Top Keywords
dosage regimen
8
hollow-fiber infection
8
optimized combination
8
mic mg/liter
8
combating carbapenem-resistant
4
carbapenem-resistant acinetobacter
4
acinetobacter baumannii
4
baumannii optimized
4
optimized imipenem-plus-tobramycin
4
imipenem-plus-tobramycin dosage
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!